Kiora Pharmaceuticals (KPRX) Change in Account Payables (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Change in Account Payables came in at -$303026.0 in Q1 2026, down 125.86% YoY from $1.2 million in Q1 2025, and down 146.2% on a QoQ basis from $655913.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Change in Account Payables (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Change in Account Payables data on file, last reported at -$303026.0 in Q1 2026.
- Quarterly Change in Account Payables fell 125.86% year-over-year to -$303026.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$349725.0 (down 127.48% YoY) and the FY2025 annual result came in at $1.1 million, up 397.49% from the prior year.
- Change in Account Payables eased to -$303026.0 in Q1 2026, from $655913.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q1 2025 to a low of -$662048.0 in Q2 2025.
- A 5-year average of $60145.2 and a median of $15012.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables surged 2461.65% — and 2025, when it sank 1030.78%.
- Tracing KPRX's Change in Account Payables over 5 years: stood at $147310.0 in 2022, then plunged by 72.42% to $40635.0 in 2023, then plunged by 653.37% to -$224863.0 in 2024, then jumped by 391.69% to $655913.0 in 2025, then sank by 146.2% to -$303026.0 in 2026.
- The last three Change in Account Payables figures came in at -$303026.0 (Q1 2026), $655913.0 (Q4 2025), and -$40564.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -378,492.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -378,492.00 |
| Jun 30, 2026 | -378,492.00 |
| Mar 31, 2026 | -303,026.00 |
| Mar 31, 2026 | -303,026.00 |
| Dec 31, 2025 | 655,913.00 |
| Dec 31, 2025 | 655,913.00 |
| Sep 30, 2025 | -40,564.00 |
| Sep 30, 2025 | -40,564.00 |
| Jun 30, 2025 | -662,048.00 |
| Jun 30, 2025 | -662,048.00 |
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | -224,863.00 |
| Dec 31, 2024 | -224,863.00 |
| Sep 30, 2024 | 384,555.00 |
| Sep 30, 2024 | 384,555.00 |
| Jun 30, 2024 | -58,548.00 |
| Jun 30, 2024 | -58,548.00 |
| Mar 31, 2024 | 124,975.00 |
| Mar 31, 2024 | 124,975.00 |